By MATTHEW HOLT I have been trying hard to suppress this line of thought but when I woke up in the middle of the night with this piece basically fully formed in my head I couldn’t not write it. Yes I might lose some friends, but someone in health tech has to say this. Last…
Legal case involves major implications for health insurance coverage nationwide
We need to embrace a more holistic, integrated approach to mental healthcare: one that combines the best of human expertise with rapid innovations of technology, all while being mindful of the real-world challenges faced by marginalized and underserved communities. The post Reimagining Mental Healthcare: We Need A New Road, Not A Bigger Truck appeared first…
Bristol Myers Squibb’s partnership with BioNTech makes it the third big pharma company to strike a deal to gain access to a PD-L1/PD-1 and VEGF bispecific antibody with potential use in drug combinations to treat cancer. The deal calls for the two companies to share in the development of BioNTech’s drug and co-commercialize the asset…
Research shows that between 2018 and 2022, industry-sponsored trials enrolled over eight times more patients than federally sponsored trials.
Shifting healthcare dollars into individual-controlled accounts would mark an inflection point. But even without full policy execution, consumer wallet economics are expanding. The race is now on to build the infrastructure layer between individual spending authority and care delivery. The post When Health Dollars Move to Individuals, Infrastructure Will Decide Who Wins appeared first on…
Pharvaris’s deucrictibant met the main and secondary goals of its Phase 3 test as an on-demand treatment for swelling attacks caused by the rare disease hereditary angioedema. Pharvaris’s capsule could compete against Kalvista Pharmaceuticals’ Ekterly, an HAE pill approved by the FDA over the summer. The post Pharvaris Drug for Rare Swelling Disease Meets Phase…
AI can speed up drug discovery and decrease attrition rates in the clinic, but it is important to recognize that both are tall orders. The companies that will benefit most are those that stay grounded, set realistic expectations, and keep experienced scientists at the center of decisions that require genuine creativity and judgment. The post…
Lōvu Health’s Series A round was led by SJF Ventures and included participation from Rogue Women’s Fund, Symphonic Capital, Emmeline Ventures and Majella Ventures. The post Lōvu Health Rakes In $8M for Maternal Health Platform appeared first on MedCity News.
There is only one difference between a bad economist and a good one: the bad economist confines himself to the visible effect; the good economist takes into account both the effect that can be seen and those effects that must be foreseen.” ― Frédéric Bastiat